Objective-Genome-wide association studies and preclinical studies demonstrated a role of sortilin in lipid metabolism, inflammation, and vascular calcification-all cardiovascular risk factors. We evaluated the association of serum sortilin levels with the risk of major adverse cerebrovascular and cardiovascular events (MACCE) and the severity of abdominal aortic calcification (AAC). Approach and Results-A cohort of community-dwelling men aged ≥50 years (n=830) was assessed. At baseline, sortilin levels were measured by ELISA, and AAC was assessed on lateral spine scans obtained by dual-energy X-ray absorptiometry. Men aged ≥60 years (n=745) were followed up prospectively for the incidence of MACCE. During the median follow-up of 7.9 years, 76 MACCE occurred. The unadjusted incidence of MACCE across increasing sortilin quartiles was 8.0, 7.4, 19.8, and 20.3 per 1000 person-years. In multivariate-adjusted analysis, sortilin associated with increased risk of MACCE (hazard ratio, 1.70 per SD; 95% confidence interval, 1.30-2.20; P<0.001). The third and fourth quartiles associated with 3.42-fold (95% confidence interval, 1.61-7.25; P<0.005) and 3.82-fold (95% confidence interval, 1.77-8.26; P<0.001) higher risk of MACCE compared with the first quartile. High sortilin also predicted MACCE independent of traditional Framingham risk factors. Higher sortilin associated with higher odds of severe AAC (score>5) after adjustment for confounders (odds ratio, 1.43 per SD; 95% confidence interval, 1.10-1.85; P<0.01). The highest sortilin quartile associated with 2-fold higher odds of severe AAC (versus 3 lower quartiles combined). After adjustment for low-density lipoprotein cholesterol, the odds of severe AAC remained significant. Conclusions-In older men, higher serum sortilin levels associated with higher MACCE risk and severe AAC independently of relevant confounders, including C-reactive protein and low-density lipoprotein cholesterol. This finding, however, needs to be validated in other cohorts. Visual Overview-An online visual overview is available for this article. 12, 19 Therefore, the primary object of the current study was to evaluate the association of serum sortilin levels with the prospectively assessed risk of major adverse cerebrovascular and cardiovascular events (MACCE) and with severe AAC in a community-dwelling cohort of men aged ≥50 years.
G enome-wide association studies have shown a strong association between the 1p13 locus and cardiovascular diseases, including myocardial infarction, 1 abdominal aortic aneurysm, 2 and aortic stenosis. 3 Variations of the 1p13.3 locus were associated with coronary artery 4 and aortic valve 5 calcification, as well as low-density lipoprotein (LDL) cholesterol (LDL-C) levels in several populations. 6 The 1p13.3 locus harbors 4 genes, CELSR2, PSRC1, MYBPHL, and SORT1. The functional role of the SORT1 gene, encoding sortilin, has been studied in vitro and in vivo. Sortilin is a multiligand sorting receptor with functional characteristics of the vacuolar protein sorting 10 protein domain family. 7 Preclinical in vivo evidence suggests a significant role of sortilin in the pathogenesis of cardiovascular and metabolic diseases, including type 2 diabetes mellitus by regulating insulin resistance, 8 atherosclerosis through arterial wall inflammation and dysregulated lipoprotein metabolism, 9,10 and vascular calcification. 11 We have recently reported that sortilin plays a key role in the development of vascular calcification by promoting the calcification potential of smooth muscle cell-derived extracellular vesicles. 11 A recent study also reported a correlation of plasma sortilin with C-reactive protein (CRP) and LDL-C-both cardiovascular risk factors. 12 The value of arterial calcification in the cardiovascular risk assessment is well established. 13 Coronary artery calcification 14, 15 and abdominal aortic calcification (AAC) 16 have been investigated as tools for cardiovascular risk assessment. 17 Severe AAC is associated with higher risk of cardiovascular morbidity and mortality because of heart attack and stroke. 18 As sortilin is reported as a proatherogenic and procalcific molecule, its serum level may be associated with cardiovascular morbidity. However, direct clinical evidence of serum sortilin as a marker for cardiovascular risk and of the role of LDL-C and vascular calcification as potential confounders of such an association is lacking. 12, 19 Therefore, the primary object of the current study was to evaluate the association of serum sortilin levels with the prospectively assessed risk of major adverse cerebrovascular and cardiovascular events (MACCE) and with severe AAC in a community-dwelling cohort of men aged ≥50 years.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Characteristics
Tables I and II in the online-only Data Supplement show characteristics of the cohort by sortilin quartiles at baseline. Higher sortilin levels were associated with younger age, lower prevalence of self-reported ischemic heart disease, less frequent treatment with statins and angiotensin-converting enzyme inhibitors, lower serum phosphorus and osteoprotegerin, as well as higher serum levels of total cholesterol (TC), LDL-C, and CRP. After adjustment for age, serum sortilin correlated positively with serum levels of TC, LDL-C, and CRP (Table III in 
Serum Sortilin Levels and Incident of MACCE
Men aged ≥60 years (n=745) were followed up prospectively. As 15 men dropped out after the first visit, prospective information was available in 730 men. Overall, 76 MACCE occurred over the median of 7.9 years of follow up (interquartile range, 7.0-8.0 years). The MACCE incidence rate was 14.2 per 1000 person-years. The unadjusted incidence of MACCE across increasing sortilin quartiles was 8.0, 7.4, 19.8, and 20.3 per 1000 person-years, respectively (Table 1) .
Figure shows the unadjusted Kaplan-Meier curves for eventfree survival by sortilin quartiles over 8 years follow-up. After adjustment for age, MACCE incidence increased with elevated sortilin concentration (hazard ratio [HR], 1.52 per SD (17.6 ng/ mL); 95% confidence interval [CI], 1.20-1.94; P<0.001). The third and fourth quartiles of sortilin associated with >2-fold higher MACCE risk compared with the first quartile. In the fully multivariate-adjusted analysis, the third and fourth quartiles of sortilin associated with a significant 3.3-fold higher MACCE risk compared with the first quartile, respectively (Table 1) .
Given the higher risk of MACCE in the third and fourth sortilin quartiles, we categorized men into low-and high-risk groups using the median value of sortilin as an appropriate cutoff. Quartile 1, <60 ng/mL; Quartile 2, 60-71 ng/mL; Quartile 3, >71-84 ng/mL; Quartile 4, >84-125 ng/mL. MACCE is defined as composite of cardiovascular death, nonfatal ST-elevation or non-ST-elevation myocardial infarction, unstable angina, and nonfatal stroke. Model 1 is adjusted for age, fat mass. Model 2 is adjusted for age, fat mass, smoking (current, former, and never), alcohol intake, and physical activity. Model 3 is adjusted for age and model 2 variables plus health status (self-reported pharmacologically treated diabetes mellitus, systolic blood pressure, AAC), and medications (vitamin K antagonist, angiotensin-converting enzyme inhibitors, diuretics, and fibrates). Model 4 is adjusted for age and model 3 variables plus biological measurements (testosterone, osteoprotegerin, LDL-C, C-reactive protein). AAC indicates abdominal aortic calcification; LDL-C, low-density lipoprotein cholesterol; MACCE, major adverse cerebrovascular and cardiovascular events; and ROC, receiver operating characteristics.
*Number of events per 1000 person-years. †P<0.001. ‡P<0.005.
(95% CI, 15.6-25.8) in men with sortilin above the median (>71 ng/mL) and 8.8/1000 person-years (95% CI, 5.7-13.1) in men with lower sortilin levels. After adjustment for other risk factors, the risk of MACCE was found to be 3-fold higher in men with sortilin above the median versus below the median. We additionally performed 2 different analyses to determine an optimal binary cutoff for the sortilin levels. First, we determined the sortilin threshold using the Youden index on the receiver operating characteristics curve analysis. The threshold of 76 ng/mL has a sensitivity of 52% and specificity of 65%.
In the fully adjusted model, men with sortilin >76 ng/mL associated with 3.1-fold higher MACCE risk compared with those below the threshold (Table 1) . We then explored the sortilin-MACCE relationship by unadjusted spline polynomials that indicated 3 sortilin groups with low, intermediate, and high cardiovascular risk ( Figure I in the online-only Data Supplement). The unadjusted incidence of MACCE increased across the sortilin levels (Table IV in the online-only Data Supplement). In the fully adjusted model, highest sortilin levels (>80 ng/mL) associated with 4-fold higher MACCE risk compared with the reference group (<60 ng/mL). Overall, the binary cutoff determined by different approaches gave very similar results regarding the MACCE risk.
Adjustment for LDL-C had no effect in the multivariate model, suggesting that the observed association of sortilin and MACCE is LDL-C independent (Table 1 ). When we substitute TC for LDL-C or combined TC and LDL-C, we obtained similar results, regardless of using LDL-C or TC as the confounding variable (Table V in the online-only Data Supplement).
Higher sortilin levels were associated with higher risk of major adverse cardiovascular event (MACE; n=43) and stroke (n=33) analyzed separately. In multivariate-adjusted analysis, the HR per SD sortilin was 1 Next, we analyzed interactions and joint effects of sortilin levels and cardiovascular risk factors associated with the outcomes. High sortilin (>71 versus ≤71 ng/mL) levels were associated with significant 5.5-, 3.4-, and 3.0-fold higher risk of MACCE in men without hypertension, diabetes mellitus, or ischemic heart disease, respectively, at baseline ( Table 2) . The MACCE risk further increased when both high sortilin levels and diabetes mellitus (HR, 4.9; P<0.001) or high sortilin levels and hypertension (HR, 7.9, P<0.001) were present at baseline. High sortilin levels and ischemic heart disease had no joint effect on MACCE. Low testosterone levels (<11.4 nmol/L) were associated with 2.9-fold higher risk of MACCE (P<0.05). Men with higher sortilin levels had a 5.8-fold increased risk of MACCE (P<0.001), independent of testosterone levels.
Association Between Serum Sortilin Levels and Severe AAC
As expected, prevalence of self-reported ischemic heart disease and AAC severity increased with age (Table VII in the online-only Data Supplement). Men self-reporting ischemic heart disease had more severe AAC, also after adjustment for age, weight, smoking, diabetes mellitus, and hypertension (Table VIII in the online-only Data Supplement). In the continuous model, serum sortilin and AAC were found to be not significantly associated. In the unadjusted model, sortilin levels did not differ across the categories of AAC severity (P=0.41; Table IX in the online-only Data Supplement).
The unadjusted and age-adjusted association between sortilin quartiles and severe AAC (AAC>5) was not significant. However, after adjustment for confounders, odds of severe AAC were higher for elevated serum sortilin levels (odds ratio, 1.43 per SD; 95% CI, 1.10-1.85; P<0.01; Table 3 ). Odds of severe AAC were higher in the highest sortilin quartile versus the lowest quartile (odds ratio, 2.19; 95% Cl, 1.12-4.30; P<0.01). Furthermore, the analysis across the quartiles suggested that there was a critical threshold at the level of the third/fourth quartile limit. Odds ratio of severe AAC was higher in the upper sortilin quartile versus the 3 lower quartiles combined (odds ratio, 1.94; 95% CI, 1.12-3.36; P<0.05). Adjustment for TC or LDL-C did not have a major impact on the association of serum sortilin and severe AAC. There was no interaction between sortilin, TC, or LDL-C levels.
Sensitivity Analysis
Additionally, the analysis was performed in the entire cohort (ie, including men with sortilin levels >125 ng/mL). In 769 men aged ≥60 years, 76 men had MACCE. Higher sortilin levels (>71 ng/mL) remained significantly associated with higher risk of MACCE (HR, 3.09; 95% CI, 1. the model instead of LDL-C, was not significant and was not retained in the final model. By contrast, all associations between sortilin and AAC lost significance.
Discussion
The present study demonstrates that in older communitydwelling men, high serum sortilin levels associate with increased MACCE risk (both MACE and stroke) after adjustment for multiple relevant confounders, including CRP, TC, and LDL-C.
Sortilin is best known for its genetic relationship to LDL-C 6 and for its role in controlling hepatic lipoprotein secretion. 20, 21 However, emerging evidence suggests a cholesterol-independent role of sortilin in cardiovascular disease. 2, 9, 11 Our data support this notion.
We tested the possible confounding effect of serum TC and LDL-C levels on the association between high serum sortilin and AAC. In our cohort, sortilin serum levels were found to be positively correlated with CRP, TC, and LDL-C levels; the data being consistent with observations in a previously published study. 12 Nevertheless, when CRP, TC, or LDL-C levels were added to the multivariate model, along with other known AAC risk factors, the sortilin-AAC association remained significant. A recent report showed that statin therapy in 90 statin-naive patients with CAD reduced sortilin serum levels by 12%. 19 In our study, treatment with statins or fibrates did not alter the association between serum sortilin and AAC, suggesting that the observed association of high serum sortilin with severe AAC might be independent of lipid abnormalities. This is in line with the cholesterol-independent role of sortilin in the development of experimental atherosclerosis 9 and vascular calcification 11 and its genetic association with abdominal aortic aneurysm predisposition. 2 We previously reported reduced atherosclerotic vascular calcification in mice lacking sortilin. 11 We demonstrated using human smooth muscle cells that sortilin is a key component of extracellular vesicles required for their calcification propensity. 11 Therefore, serum sortilin levels are likely to reflect the susceptibility to aortic calcification.
In this study, high serum sortilin levels associated with 3-fold higher risk of MACCE after adjustment for potential confounders, including CRP, TC, and LDL-C. AAC is n/N (%) indicates number of MACCE per number quartile of serum sortilin level. MACCE is defined as composite of cardiovascular death, nonfatal ST-elevation or non-ST-elevation myocardial infarction, unstable angina, and nonfatal stroke. All the models adjusted for age, fat mass, smoking (current, former, and never) and physical activity, vitamin K antagonist, angiotensin-converting enzyme inhibitors, diuretics, fibrates, osteoprotegerin, LDL-C, C-reactive protein and mutually exclusively for testosterone, self-reported pharmacologically treated diabetes mellitus, and systolic blood pressure. CI indicates confidence interval; HR, hazard ratio; LDL-C, lowdensity lipoprotein cholesterol; and MACCE, major adverse cerebrovascular and cardiovascular events. *> vs ≤median.
an independent predictor of cardiovascular morbidity and mortality. 17 Further, AAC can predict coronary artery calcification 22 -one of the strongest predictors of MACCE. 14, 23 However, the association between sortilin and MACCE remained significant after adjustment for AAC, suggesting that this association cannot be solely explained by the cofounding effect of AAC visible on a dual-energy x-ray absorptiometry scan. The previous observation that the density of calcification present within the arterial plaque inversely correlates with cardiovascular morbidity showed that the pattern/density of calcification is an important variable in addition to the calcification volume in predicting cardiac events. 24 Low-density calcification, so-called spotty calcification or microcalcification, in the fibrous cap promotes atherosclerotic plaque instability and rupture-the leading cause of myocardial infarction. 25 However, whether this represents a causal relationship or large atherosclerotic calcification adds protective features to plaques and serves as a surrogate marker for disease is still of debate. Recently, we found that vascular smooth muscle cell-derived calcifying extracellular vesicles are precursors of microcalcifications in the atherosclerotic plaque 26 and that sortilin regulates their calcification competence. 11 In mice and humans, high-resolution imaging techniques identified small microcalcifications that may contribute to plaque rupture risk. 27, 28 These microcalcifications are smaller than the detection limit of dual-energy x-ray absorptiometry scans, which may explain the remaining association between sortilin and MACCE. Therefore, future studies are required to determine whether calcification located in the tunica media of the abdominal aorta reflects the overall cardiovascular calcium burden and the presence of microcalcification.
Importantly, experimental data reveals a role for sortilin in type 2 diabetes mellitus by regulating insulin resistance, 8 as well as in the development of atherosclerotic lesions, by controlling the interleukin-6 release from inflammatory cells, 9 LDL-uptake into macrophages, 10 or involvement in platelet activation 12 -the risk factors for cardiovascular events that may contribute to the sortilin association with MACCE risk. In our cohort, high serum sortilin was associated with MACCE independently of hypertension, diabetes mellitus, or decreased testosterone levels-all cardiovascular risk factors. [29] [30] [31] Thus, sortilin seems to be associated with MACCE risk even in individuals without these cardiovascular risk factors, suggesting that it may act through independent mechanisms.
Our study limitation is the exclusive examination of men. Elderly men are the population with the highest risk for atherosclerosis and cardiovascular diseases. The high incidence of cardiovascular emergencies evaluated in our study is a major public health problem in the developed countries. The study in a high-risk group provides a foundation for the future studies to explore sortilin as a biomarker in other populations. In addition, 2 genetic studies found that only male carriers of the minor (protective) allele of rs646776 within the Sort locus had significant changes in LDL-C levels, while female subjects were unaffected. 32, 33 Genetic reports, however, do not provide causality and do not allow a conclusion about an association with serum sortilin levels. In addition, our work does not suggest the impact of sex hormones because the association between sortilin and testosterone levels was not significant. A previous report on serum sortilin levels and depression did not identify sex-dependent differences in serum sortilin either. 34 Therefore, it is unlikely that serum sortilin levels in male and female would differ. The study limitations further include a relatively small sample size from a single center that represents a homogenous group in terms of ethnicity and geography. Older volunteers for an epidemiological study may be a healthier group and not representative of their age range. Chronic diseases were self-reported, and no formal adjudication was performed. Blood was taken under nonfasting conditions. Because sortilin is mainly secreted by the liver, 6 it cannot be excluded that sortilin serum levels are affected by food intake. Men aged >65 years are at risk for abdominal aortic aneurysm, which was genetically linked to sortilin 2 and, hence, should be an adjusting variable in our study. Dual-energy x-ray absorptiometry cannot detect abdominal aortic aneurysm; therefore, a correction for it was not possible. Our definition of sudden cardiac death does not exclude death from intracerebral bleeding, aortic dissection, or fulminant pulmonary embolism. Although our analyses were assessed for potential confounding effect of various factors and the final models adjusted for relevant confounders, a significant association because of the residual variability cannot be excluded. In summary, we showed that in older men, high serum sortilin levels are associated with increased MACCE risk after adjustment for multiple confounders, including CRP and LDL-C. Many genetic studies focus on possible relationship between variations in the sort locus and cardiovascular disease; however, clinical implications of results from genomewide association studies are rare. Our study, therefore, provides valuable information about the potential use of sortilin as a new cardiovascular risk marker. Nonetheless, before a clinical value of sortilin levels can be proposed, our findings must be validated in de novo independent cohorts and a potential predictive value of sortilin has to be compared with other widely recognized and validated cardiovascular biomarkers.
Future studies are needed to connect the prospective clinical observations to the mechanistic findings on sortilin in cardiovascular calcification, lipid metabolism, and inflammation. A limitation of epidemiological studies is that the specific mechanisms cannot be dissected. These studies may instead explore clinically relevant risk factors and provide valuable information for the future mechanistic studies. Our recent study reported specific molecular mechanisms for sortilin's action, 11 and the present study has linked serum sortilin levels and cardiovascular risk. Future investigations are warranted to probe the mechanistic relationship between circulating sortilin and cardiovascular events. If a causal relationship is found, sortilin may serve as both a diagnostic biomarker and a therapeutic target for cardiovascular disease.
Our experimental data associated sortilin with microcalcifications in vitro and in vivo. 11 A correlation of serum sortilin levels with coronary artery calcification and valve calcification, however, should be validated via high resolution imaging of subclinical calcification. The potential promise for clinical applications must await large-scale and multicenter, prospective follow-up studies involving men and women that can both validate the findings of our study and demonstrate clinical utility of serum sortilin in cardiovascular risk prediction, in particular for the identification of patients at high MACCE risk.
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